 | Up a level |
Journal Article
Abdulla, D. S. Y., Nogova, L., Riedel, R., Scheftler, M., Fischer, R. N., Michels, S., Heydt, C., Ihle, M. A., Fassunke, J., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2018). NTRK1/2/3 gene rearrangements define a new and clinically actionable molecular subset of oncogene-driven cancers. Oncol. Res. Treat., 41. S. 293 - 294. BASEL: KARGER. ISSN 2296-5262
Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A., Frank, S., Holz, B., Binot, E., Kron, A., Merkelbach-Bruse, S., Ihle, M., Wolf, J., Buettner, R. and Schultheis, A. M. (2018). Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations. Virchows Arch., 473. S. S315 - 1. NEW YORK: SPRINGER. ISSN 1432-2307
Ball, M., Fassunke, J., Heydt, C., Fischer, J., Schallenberg, S., Joehrens, K. and Merkelbach-Bruse, S. (2020). External quality assessment of immunohistochemistry, in-situ hybridization and RNA/DNA sequencing for ROS1 testing reveals high concordance for all methods. Ann. Oncol., 31. S. S890 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Brandes, V, Scheffler, M., Kambartel, K., Ortiz-Cuaran, S., Scheel, A., Michels, S., Nogova, L., Fischer, R., Abdulla, D., Merkelbach-Bruse, S., Buettner, R., Sos, M. L. and Wolf, J. (2016). Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262
Castiglione, R., Alidousty, C., Wagener, S., Holz, B., Kron, A., Wolf, J., Merkelbach-Bruse, S., Reinhardt, C., Buettner, R. and Schultheis, A. M. (2018). Genetic MET alterations in non-small cell lung cancer: biologic differences and analogies. Virchows Arch., 473. S. S17 - 1. NEW YORK: SPRINGER. ISSN 1432-2307
Castiglione, R., Ihle, M. A., Heydt, C., Alidousty, C., Schultheis, A., Merkelbach-Bruse, S., Hermsen, M., Buettner, R. and Franchi, A. (2017). Molecular characterisation of sinunasal carcinomas. Virchows Arch., 471. S. S150 - 1. NEW YORK: SPRINGER. ISSN 1432-2307
Castiglione, R., Ihle, M. A., Merkelbach-Bruse, S., Hartmann, W. and Buettner, R. (2016). EGFR mutations in sinonasal Squamous Cell Carcinoma (SCC) and papilloma. Virchows Arch., 469. S. S195 - 2. NEW YORK: SPRINGER. ISSN 1432-2307
Dietmaier, W., Merkelbach-Bruse, S. and Dahl, E. (2014). Report of the Working Group on Molecular Pathology 2014. Pathologe, 35. S. 298 - 300. NEW YORK: SPRINGER. ISSN 1432-1963
Dietmaier, W., Merkelbach-Bruse, S., Jung, A. and Lehmann, U. (2016). Report on sessions and the general meeting of the working group Molecular Pathology. Pathologe, 37. S. 249 - 253. NEW YORK: SPRINGER. ISSN 1432-1963
Dietmaier, W., Penzel, R. and Merkelbach-Bruse, S. (2013). Report on the General Assembly of the Working Group on Molecular Pathology during the 97th Annual Meeting of the German Society for Pathology (DGP) in Heidelberg. Pathologe, 34. S. 295 - 297. NEW YORK: SPRINGER. ISSN 1432-1963
Eisert, A., Scheffier, M., Gogl, L., Frank, R., Scheel, A., Merkelbach-Bruse, S., Michels, S., Fischer, R., Buettner, R. and Wolf, J. (2015). Clinical and genetic presentation of high-level cMET-amplified Non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Oncol. Res. Treat., 38. S. 16 - 17. BASEL: KARGER. ISSN 2296-5262
Eisert, A., Scheffler, M., Frank, R., Gogl, L., Scheel, A., Merkelbach-Bruse, S., Michels, S., Fischer, R., Buttner, R. and Wolf, J. (2015). Clinical and genetic presentation of high-level cMET-amplified Non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Eur. J. Cancer, 51. S. S646 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Eisert, A., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications. Oncol. Res. Treat., 37. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262
Eisert, A. K., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y., Gerigk, U., Geist, T., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). GENETIC VARIABILITY AND CLINICAL PRESENTATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET-AMPLIFICATIONS. Ann. Oncol., 25. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Fischer, A. K., Reuter-Jessen, K., Schildhaus, H-U, Hugo, T., Scheel, A. H., Merkelbach-Bruse, S., Heinmoeller, E., Buettner, R., Jasani, B., Walbeck, J., Rueschoff, J. and Middell, P. (2020). Development of high-risk HPV associated cervical dysplasia despite HPV-vaccination: a regional dysplasia center cohort study. Eur. J. Gynaecol. Oncol., 41 (1). S. 80 - 85. WAN CHAI: IMR PRESS. ISSN 0392-2936
Frangenberg, A., Starbatty, B., Berressem, S., Frangenberg, A., Sueptitz, J., Hayn, A., Hagmeyer, L., Wragge, S., Hellmessen, K., Merkelbach-Bruse, S., Ueckeroth, F., Hekmat, K., Frank, K., Randerath, W., Buettner, R. and Wolf, J. (2018). Implementation of Next Generation Sequencing-based Molecular Diagnostics in a Lung Cancer Center Tumor Board. Oncol. Res. Treat., 41. S. 117 - 118. BASEL: KARGER. ISSN 2296-5262
Frank, R., Scheffler, M., Michels, S., Eisert, A., Fischer, R., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. D., Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2015). KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 51. S. S645 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Frank, R., Scheffler, M., Michels, S., Eisert, A., Gogl, L., Fischer, R., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2015). KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC). Oncol. Res. Treat., 38. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262
Frank, R., Scheffler, M., Michels, S., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2014). Occurrence and characteristics of KEAP1-mutations in patients with non-small cell lung cancer (NSCLC). Oncol. Res. Treat., 37. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262
Gautschi, O., Pall, G., Schultheis, A., Keller, F. Aebersold, Gardizi, M., Heuckmann, J., Merkelbach-Bruse, S., Diebold, J., Wolf, J. and Heukamp, L. (2014). LUNG ADENOCARCINOMA WITH RET FUSION: EARLY EXPERIENCE WITH DIAGNOSIS AND TARGETED THERAPY. J. Thorac. Oncol., 9 (4). S. S38 - 1. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1556-1380
Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J. and Scheffler, M. (2022). The biological effect of small-scale ROS1 aberrations: An in silico analysis. Ann. Oncol., 33 (7). S. S1327 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Ann. Oncol., 33. S. S56 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Ann. Oncol., 33 (8). S. S1386 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Gogl, L., Scheffier, M., Ihle, M., Michels, S., Fischer, R., Serke, M., Gerigk, U., Woempner, C., Krueger, S., Kaminsky, B., Schulte, W., Hoeffken, G., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2015). Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Oncol. Res. Treat., 38. S. 269 - 270. BASEL: KARGER. ISSN 2296-5262
Gogl, L., Scheffler, M., Ihle, M., Michels, S. Y. F., Fischer, R., Serke, M. H., Gerigk, U., Woempner, C., Krueger, S., Kaminsky, B., Schulte, W., Hoeffken, G., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2015). Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Eur. J. Cancer, 51. S. S647 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Heydt, C., Baar, T., Wagener, S., Ihle, M. A., Carl, C., Fassunke, J., Buettner, R. and Merkelbach-Bruse, S. (2017). Comparison of custom designed gene panels for hybrid capture-based parallel sequencing in molecular pathology routine diagnostics. J. Mol. Diagn., 19 (2). S. S50 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811
Heydt, C., Kostenko, A., Merkelbach-Bruse, S., Wolf, J. and Buttner, R. (2016). ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology. Ann. Oncol., 27. S. 25 - 35. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Heydt, C., Pappesch, R., Rehker, J., Wagener, S., Ihle, M. A., Siemanowski, J., Buettner, R., Fassunke, J. and Merkelbach-Bruse, S. (2018). Comparison of DNA- and RNA-based parallel sequencing approaches for the detection of MET Exon 14 skipping mutations. Virchows Arch., 473. S. S288 - 1. NEW YORK: SPRINGER. ISSN 1432-2307
Heydt, C., Pappesch, R., Stecker, K., Neumann, J., Buettner, R. and Merkelbach-Bruse, S. (2018). Evaluation of the TruSight Tumor 170 (TST170) assay and its value in clinical research. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Holzem, A., Nogova, L., Ihle, M. A., Woempner, C., Bitter, E., Michels, S., Fischer, R. N., Kron, A., Gerigk, U., Kern, J., Kaminsky, B., Randerath, W. J., Lorenz, J., Kambartel, K., Merkelbach-Bruse, S., Buttner, R., Scheffler, M. and Wolf, J. (2018). Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations. Oncol. Res. Treat., 41. S. 250 - 251. BASEL: KARGER. ISSN 2296-5262
Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J. and Loges, S. (2022). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM). Ann. Oncol., 33 (6). S. 602 - 616. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Koenig, K., Peifer, M., Bos, M., Nogova, L., Merkelbach-Bruse, S., Stamm, K., Henkel, T., Thomas, R., Wolf, J., Buettner, R. and Heukamp, L. (2014). High throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathological routine diagnostics for a regional health care provider network. Oncol. Res. Treat., 37. S. 31 - 33. BASEL: KARGER. ISSN 2296-5262
Koitzsch, U., Heydt, C., Divakar, K., Attig, H., Fassunke, J., Merkelbach-Bruse, S., Fammartino, A. Alessandro, Buettner, R., Kong, Y. and Odenthal, M. (2017). Analysis of Clinical Relevant Mutations by the Novel Gene Reader NGS System. J. Mol. Diagn., 19 (2). S. S55 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811
Koleczko, S., Schaepers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Brandes, V., Abdulla, D., Ueckeroth, F., Thurat, M., Frank, R., Eisert, A., Bitter, E., Woempner, C., Gogl, L., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Koleczko, S., Schapers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Serke, M., Kaminsky, B., Benedikter, J., Bruemmendorf, T. H., Ficker, J. H., Lorenz, J., Schulte, C., Schulze-Olden, S., Brandes, V, Abdulla, D., Ueckeroth, F., Thurat, M., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Oncol. Res. Treat., 39. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. -P, Buettner, R. and Wolf, J. (2015). Comprehensive multiplex genotyping in lung cancer: challenges and opportunities of interdisciplinary networking using the example of the Network Genomic Medicine. Oncol. Res. Treat., 38. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262
Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. P., Buettner, R. and Wolf, J. (2015). Broad implementation of next generation sequencing based lung cancer genotyping in clinical routine within a nationwide health care provider network in Germany. Eur. J. Cancer, 51. S. S597 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262
Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. 
ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J.
(2018).
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Ann. Oncol., 29 (10).
S. 2068 - 2076.
OXFORD:
OXFORD UNIV PRESS.
ISSN 1569-8041
Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Nogova, L., Fischer, R., Ueckeroth, F., Abdulla, D., Kron, F., Pauli, B., Kaminsky, B., Braess, J., Graeven, U., Grohe, C., Krueger, S. ORCID: 0000-0002-1658-5993, Buettner, R. and Wolf, J.
(2017).
Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine.
Ann. Oncol., 28.
OXFORD:
OXFORD UNIV PRESS.
ISSN 1569-8041
Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262
Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262
Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2022). EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann. Oncol., 33 (7). S. S1006 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Livingstone, E., Zaremba, A., Horn, S., Ugurel, S., Casalini, B., Schlaak, M., Hassel, J. C., Herbst, R., Utikal, J. S., Weide, B., Gutzmer, R., Meier, F., Koelsche, C., Hadaschik, E., Sucker, A., Reis, H., Merkelbach-Bruse, S., Siewert, M., Sahm, F., von Deimling, A., Cosgarea, I., Zimmer, L., Schadendorf, D., Schilling, B. and Griewank, K. G. (2020). GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. Br. J. Dermatol., 183 (5). S. 928 - 940. HOBOKEN: WILEY. ISSN 1365-2133
Merkelbach-Bruse, S., Rehker, J., Siemanowski, J. and Klauschen, F. (2019). Detection and interpretation of somatic variants inmolecular pathology. Pathologe, 40 (3). S. 243 - 250. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963
Michels, S., Brandes, V, Thurat, M., Nogova, L., Scheffler, M., Fischer, R., Merkelbach-Bruse, S., Hellmich, M., Buettner, R. and Wolf, J. (2016). EATON: An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generation EGFR TKI therapy - a trial in preparation. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262
Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262
Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262
Michels, S., Heydt, C., Deschler-Baier, B., Ruesseler, V., Stratmann, J., Steinhauser, S., Fischer, R., Scheffler, M., Fassunke, J., Kron, A., Griesinger, F., Gautschi, O., Sebastian, M., Hellmich, M., Heukamp, L., Merkelbach-Bruse, S., Bttner, R. and Wolf, J. (2017). Molecular panel sequencing of pre-treatment samples reveals mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients. Oncol. Res. Treat., 40. S. 134 - 135. BASEL: KARGER. ISSN 2296-5262
Michels, S., Plenker, D., Wagener, S., Scheffler, M., Nogova, L., Abdulla, D., Riedel, R., Bunck, A., Merkelbach-Bruse, S., Buettner, R., Sos, M. and Wolf, J. (2017). Loss of ROS1 G2032R resistance mutation upon chemotherapy treatment enables successful crizotinib rechallenge in a ROS1-rearranged NSCLC patient. Oncol. Res. Treat., 40. S. 232 - 233. BASEL: KARGER. ISSN 2296-5262
Michels, S., Schultheis, A., Scheffler, M., Rosner, T., Merkelbach-Bruse, S., Heukamp, L., Engel-Riedel, W., Serke, M., Krueger, S., Benedikter, J., Gerigk, U., Schulte, W., Draube, A., Ko, Y. D., Buettner, R. and Wolf, J. (2014). RET rearrangement in adenocarcinoma of the lung. Oncol. Res. Treat., 37. S. 6 - 7. BASEL: KARGER. ISSN 2296-5262
Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262
Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262
Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R. and Wolf, J. (2020). FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Oncol. Res. Treat., 43 (SUPPL 4). S. 146 - 148. BASEL: KARGER. ISSN 2296-5262
Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Masouleh, Kharabi B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R. N., Abdulla, D. S. Y., Thomas, R., Buettner, R. and Wolf, J. (2018). FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress). Oncol. Res. Treat., 41. S. 294 - 295. BASEL: KARGER. ISSN 2296-5262
Ortiz-Bruechle, N., Muders, M., Toma, M., Esposito, I, Hartmann, A., Stoehr, R., Reis, H., Wild, P., Koellermann, J., Bremmer, F., Leichsenring, J., Stenzinger, A., Merkelbach-Bruse, S., Kirfel, S., Perner, S., Hartmann, N., Roth, W., Jung, A., Kirchner, T., Schwamborn, K., Pfarr, N., Dahl, E., Knuechel, R. and Gaisa, N. T. (2020). Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group. Urologe, 59 (3). S. 318 - 326. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Pasternack, H., Fassunke, J., Plum, P., Chon, S., Merkelbach-Bruse, S., Bruns, C., Perner, S., Hallek, M., Buttner, R., Zander, T., Quaas, A., Weiss, J. and Alakus, H. (2017). Detection of Somatic Alterations in Circulating Cell-free DNA of Esophageal Carcinoma Patients during Primary Staging is Predictive for Post-surgical Tumor Recurrence. J. Mol. Diagn., 19 (2). S. S37 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811
Pfarr, N. and Merkelbach-Bruse, S. (2021). Homologous recombination repair deficiency as a predictive biomarker Basic mechanisms and detection methods. Pathologe, 42 (4). S. 391 - 399. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963
Quaas, A., Waldschmidt, D., Alakus, H., Zander, T., Heydt, C., Goeser, T., Daheim, M., Kasper, P., Plum, P., Bruns, C., Brunn, A., Roth, W., Hartmann, N., Bunck, A., Schmidt, M., Goebel, H., Tharun, L., Buettner, R. and Merkelbach-Bruse, S. (2018). Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel. BMC Gastroenterol., 18. LONDON: BIOMED CENTRAL LTD. ISSN 1471-230X
Reguart, N., Pare, L., Gimenez-Capitan, A., Teixido, C., Galvan, P., Viteri, S., Rodriguez, S., Peg, V., Aldeguer, E., Ovalle, E., Vinolas, N., Merkelbach-Bruse, S., Lopez-Rios, F., Rosell, R., Molina-Vila, M. A. and Prat, A. (2016). Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Rehker, J., Ball, M., Heydt, C., Buettner, R. and Merkelbach-Bruse, S. (2020). Softclipping of gene specific primers after primer extension enrichment to remove artificial sequences from downstream analysis. Eur. J. Hum. Genet., 28 (SUPPL 1). S. 645 - 646. LONDON: SPRINGERNATURE. ISSN 1476-5438
Riedel, R., Michels, S., Heydt, C., Nogova, L., Fischer, R. N., Abdulla, D. S. Y., Scheffler, M., Merkelbach-Bruse, S., Kobe, C., Schaefer, S., Buettner, R. and Wolf, J. (2018). Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression. Oncol. Res. Treat., 41. S. 295 - 297. BASEL: KARGER. ISSN 2296-5262
Rosswog, C., Fassunke, J., Schoemig-Markiefka, B., Merkelbach-Bruse, S., Ackermann, S., Ortmann, M., Schulte, J., Westermann, F., Berthold, F., Simon, T., Hero, B. and Fischer, M. (2020). ALK Mutations in Primary and Relapsed Neuroblastoma in a GPOH Cohort. Pediatr. Blood Cancer, 67. S. S57 - 2. HOBOKEN: WILEY. ISSN 1545-5017
Scheffler, M., Abdulla, D. S. Y., Koleczko, S., Ihle, M. A., Merkelbach-Bruse, S., Michels, S., Nogova, L., Kron, A., Fischer, R., Serke, M., Ko, Y. -D., Gerigk, U., Schulte, W., Sebastian, M., Riedel, R., Holzem, A., Kambartel, K. -O., Buettner, R. and Wolf, J. (2017). Genetic heterogeneity of KRAS-mutated NSCLC leads to different responses to first-line platinum-based chemotherapy. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Michels, S., Gardizi, M., Koenig, K., Merkelbach-Bruse, S., Stamm, K., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). DDR2 mutations in non-small cell lung cancer (NSCLC): clinical, histological and genetic characteristics. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R. and Wolf, J. (2020). KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Oncol. Res. Treat., 43 (SUPPL 4). S. 139 - 140. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Schultheis, A., Michels, S., Teixido, C., Hartmann, W., Merkelbach-Bruse, S., Sebastian, M., Serke, M., Kropf-Sanchen, C., Wittersheim, M., Puetz, K., Binot, E., Schildhaus, H. -U., Heukamp, L. C., Rosell, R., Buettner, R. and Wolf, J. (2014). ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262
Siemanowski, J., Buhl, T., Schomig-Markiefka, B., Siebolts, U., Haak, A., Dietmaier, W., Arens, N., Buttner, R. and Merkelbach-Bruse, S. (2020). Difficulties in Analyzing Microsatellite Instability in Endometrial Cancer - the Pros and Cons of Four Different PCR-Based Testing Approaches. J. Mol. Diagn., 22 (5). S. S9 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811
Vollbrecht, C., Mairinger, F. D., Schweighofer, C. D., Heukamp, L. C., Merkelbach-Bruse, S., Buettner, R. and Odenthal, M. (2014). Testing cancer related gene panels for high throughput parallel sequencing. Eur. J. Cancer, 50. S. S145 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Wagener, S., Heydt, C., Fassunke, J., Ihle, M. A., Carl, C., Buttner, R. and Merkelbach-Bruse, S. (2017). Specific and Reliable Detection of NTRK Rearrangements in IHC-Positive FFPE Samples of Solid Tumours by Nanostring Technology. J. Mol. Diagn., 19 (2). S. S33 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811
Wagener, S., Ihle, M. A., Alidousty, C., Heydt, C., Fassunke, J., Merkelbach-Bruse, S. and Buettner, R. (2018). The potential biomarkerHR23b regulates sensitivity towards histone deacetylase inhibitors (HDACi) via the NGFR death receptor pathway. Virchows Arch., 473. S. S1 - 1. NEW YORK: SPRINGER. ISSN 1432-2307
Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R. and Wolf, J. (2020). Small Cell Lung Cancer - Filling the gap between science and patients. Oncol. Res. Treat., 43 (SUPPL 4). S. 154 - 155. BASEL: KARGER. ISSN 2296-5262
Weichert, W., Bartels, S., Baretton, G., Braicu, E. I., Demes, M. C., Endris, V., Herold, S., Heukamp, L., Hummel, M., Lehmann, U., Merkelbach-Bruse, S., Pfarr, N., Rad, R., Sehouli, J., Siemanowski, J., Stenzinger, A., von Schwarzenberg, K., Vollbrecht, C., Wild, P. and Zocholl, D. (2021). Concordance between multiple HRD assays is substantial in high-grade ovarian cancer. Ann. Oncol., 32. S. S747 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Weichert, W., Bartels, S., Braicu, I., Christinat, Y., Demes, M., Endris, V., Herold, S., Heukamp, L. C., Hummel, M., Lehmann, U., Merkelbach-Bruse, S., Pfarr, N., Rad, R., Sehouli, J., Siemanowski, J., Stenzinger, A., von Schwarzenberg, K., Vollbrecht, C., Wild, P. J. and Zocholl, D. (2022). High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer. Ann. Oncol., 33 (7). S. S808 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041